What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Zanubrutinib shows moderate clinical effectiveness compared to standard care, particularly in patients who have had prior treatment. The ASPEN study indicates a very good partial response rate of 28.4% for zanubrutinib, which is higher than the 19.2% for ibrutinib, although the overall survival data remains immature. The committee acknowledged that while zanubrutinib is effective, the size of the benefit compared to bendamustine plus rituximab (BR) and dexamethasone plus rituximab and cyclophosphamide (DRC) is uncertain, leading to a rating of A.
Does the economic case hold at the expected price? — Cost effectiveness
Zanubrutinib is considered cost-effective when used after at least one prior treatment, with an ICER under £30,000 per QALY gained when compared to BR. However, the cost-effectiveness estimates for patients who have not had prior treatment are above acceptable thresholds, which introduces some context-dependent variability. Overall, the evidence supports a rating of A.
Is there quality-of-life evidence payers weigh? — Quality of life
The patient expert testimony highlighted significant improvements in quality of life with zanubrutinib, allowing for better daily functioning and reduced hospital visits compared to traditional chemoimmunotherapy. The oral administration of zanubrutinib is particularly valued, addressing a significant unmet need in this patient population. This strong qualitative evidence supports a rating of A+.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Zanubrutinib has a very good safety profile, with manageable adverse reactions reported. The committee noted that it is better tolerated than existing chemoimmunotherapy options, which often lead to severe adverse reactions. This strong safety profile justifies a rating of A+.
Was the drug compared against what payers expect? — Comparator Selection
The clinical evidence primarily compared zanubrutinib with ibrutinib, which was deemed not relevant for this appraisal. The relevant comparators, BR and DRC, were not directly compared in the ASPEN study, leading to a reliance on indirect comparisons that introduce uncertainty. This suboptimal comparator selection results in a rating of B++.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in the ASPEN study is considered broadly representative of the intended patient population in the Healthcare, with a significant proportion of patients having had prior treatments. The committee noted that the trial included patients with both MYD88 mutation types, enhancing generalizability. Minor gaps in subgroup analysis do not detract from the overall representativeness, supporting a rating of A+.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Zanubrutinib can be integrated into existing care pathways with minor adjustments, primarily due to its oral administration and manageable side effects. The committee noted that it would not require significant changes to current treatment protocols, justifying a rating of A+.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of zanubrutinib is manageable, particularly when considering the patient access scheme that provides a discount. The committee concluded that the resource implications are justifiable given the clinical benefits, supporting a rating of A.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from the ASPEN study, a well-structured RCT, although there are some limitations regarding the maturity of survival data. The committee found the evidence credible and robust enough for decision-making, leading to a rating of A.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness and survival data for zanubrutinib, particularly in the context of indirect comparisons with BR and DRC. The committee acknowledged these uncertainties, which could impact broader implications for treatment pathways, resulting in a rating of B++.
